Proving It in the Real World
CASCADE-LUNG is a prospective clinical study validating DELFI’s AI-driven approach to lung cancer screening in thousands of real-world patients. Using whole-genome sequencing to analyze cell-free DNA fragmentation patterns from a simple blood draw, the study aims to demonstrate sensitivity, specificity, and predictive value in the population most in need of screening.
The Science Behind Improved Cancer Detection
DELFI's AI-driven computational platform analyzes genome-wide patterns of cell-free DNA fragmentation from a simple blood draw, using machine learning to detect cancer signals that conventional approaches miss. First published in Nature, our technology examines the whole genome rather than looking for individual mutations, giving researchers and clinicians a broader, more sensitive view of cancer biology.
Screening Starts with a Simple Blood Draw
FirstLook Lung is a blood-based lung cancer screening test designed and proven for large-scale health system deployment, with EHR integration, provider support, and established clinical workflows already in place. Designed for adults eligible under USPSTF guidelines, it uses AI and whole genome sequencing to help identify individuals at higher risk for lung cancer before or alongside low-dose CT. With 99.8% negative predictive value, FirstLook gives providers and patients a convenient, noninvasive way to take the first step.
Join Our Team
We’re building the future of cancer screening and detection. Join a team of scientists, engineers, and commercial leaders working to make early screening accessible for everyone who needs it.